{"disease":{"id":"adenocarcinoma-stomach","name":"adenocarcinoma stomach"},"drugs":{"marketed":[{"drug_id":"ramucirumab","indication_name":"Adenocarcinoma of stomach","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyramza","generic_name":"RAMUCIRUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor receptor 2","drug_class":"Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]","quality_score":10,"revenue":"900","mechanism":"Cyramza blocks the VEGFR2 receptor, which is involved in cancer cell growth and spread."},{"drug_id":"mitomycin","indication_name":"Disseminated adenocarcinoma of the stomach or pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03030404","title":"Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":733,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06277908","title":"Postoperative Morbidity and Mortality After Gastric Cancer Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"P. Herzen Moscow Oncology Research Institute","has_results":false},{"nct_id":"NCT02625610","title":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT06790238","title":"POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Grupo Español de Rehabilitación Multimodal","has_results":false},{"nct_id":"NCT05872685","title":"Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT03647969","title":"Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":262,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06028737","title":"Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Ukrainian Society of Clinical Oncology","has_results":false},{"nct_id":"NCT04878783","title":"Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"University of Roma La Sapienza","has_results":false},{"nct_id":"NCT05729646","title":"Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT03722108","title":"Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06362070","title":"Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Azienda Ospedaliera Universitaria Integrata Verona","has_results":false},{"nct_id":"NCT07341737","title":"SL-28 for Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Second Life Therapeutics","has_results":false},{"nct_id":"NCT06121700","title":"Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07007182","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":54,"lead_sponsor_name":"Jinbo Yue","has_results":false},{"nct_id":"NCT07353684","title":"Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT04660929","title":"CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Carisma Therapeutics Inc","has_results":false},{"nct_id":"NCT07334431","title":"Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT03979131","title":"Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Vall d'Hebron Institute of Oncology","has_results":false},{"nct_id":"NCT05012397","title":"Milademetan in Advanced/Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Rain Oncology Inc","has_results":true},{"nct_id":"NCT02202759","title":"A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06992362","title":"Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07178340","title":"Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05715931","title":"Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT05970627","title":"Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Yu jiren","has_results":false},{"nct_id":"NCT02564367","title":"Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT06646783","title":"Phase IIT Trial of SNA014","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"SmartNuclide Biopharma","has_results":false},{"nct_id":"NCT07014254","title":"Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT01212822","title":"Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":true},{"nct_id":"NCT04077255","title":"EGFR-targeted Therapy for Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":19,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT02830594","title":"Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06299163","title":"NM32-2668 in Adult Patients With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Numab Therapeutics AG","has_results":false},{"nct_id":"NCT05315830","title":"A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"The First Affiliated Hospital of Bengbu Medical University","has_results":false},{"nct_id":"NCT01939275","title":"64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05311176","title":"A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Imugene Limited","has_results":true},{"nct_id":"NCT07283848","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02344810","title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Eastern Cooperative Oncology Group","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}